Gilead Lands Galapagos’ Filgotinib After AbbVie Walks Away
By Heather Cartwright & Keshav Mahawar
Pharma Deals Review: Vol 2016 Issue 2 (Table of Contents)
Published: 9 Feb-2016
DOI: 10.3833/pdr.v2016.i2.2142 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Making clear its ambitions in the inflammatory disease space, Gilead Sciences has formed a global partnership with Belgian biotech Galapagos for the development and commercialisation of the Phase III-ready JAK1 (Janus kinase 1) inhibitor filgotinib, committing US$725 M upfront in cash and equity...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS